WNTRESEARCH AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.067 SEK | -.--% |
|
-.--% | -27.17% |
| May. 03 | WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 29 | WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
WntResearch AB is a Sweden-based company engaged in the translational cancer research. Its aim is to develop anti-metastatic therapies based on an increased understanding of the mechanisms underlying the metastatic process and the evaluation of specific small molecules that can specifically interact with this process. The Companyâs programs focus on the role of the Wnt-5a protein in the metastatic process. As of December 31, 2011, the Company had two projects, namely Foxy-5 and Box-5. Foxy-5 is a hexapeptide mimicking the effects of WNT-5a. Box-5 is a peptide antagonizing the effects of Wnt-5a. As of March 31, 2012, the Companyâs largest shareholder was Forskarpatent I Syd AB, which held 26.55% shares.
Calendar
2024-08-21
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -27.17% | 5.42M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- WNT Stock
- News WntResearch AB
- WntResearch : to Look for New CEO as Acting Chief Steps Down